DEEP Trust unveils mobile health and screening bus

IMT News Desk
IMT News Desk
· 2 min read

DEEP Trust also launched the DEEP Mobile App

DEEP Trust, a collective of Doctors and Responsible citizens, a non-profit organisation working to uplift vulnerable children and communities celebrated 11th anniversary with DEEP Annual Day – DEEP Elevate 2025. A major highlight of DEEP Elevate 2025 was the launch of the DEEP Mobile Health & Screening Bus, a fully equipped mobile facility designed to deliver preventive healthcare directly to underserved communities. The mobile unit provides free breast cancer screening, cervical cancer screening, basic diagnostics, and essential health education, enabling early detection of diseases and reducing the financial burden associated with late-stage treatment. By reaching remote and low-resource areas, the initiative is expected to benefit thousands of women and families, significantly strengthening community health outcomes.

The Mobile Health and Screening Bus was formally unveiled by Dr Madhu Vasepalli, Founder and Trustee, Swati Mohanti, Trustee, Priya Ieyngar, Legal Advisor, Dr Arya Yashashree, Volunteer and Phanindra, Manager Communications.

On this occasion, DEEP Trust also launched the DEEP Mobile App, a user-friendly digital platform that enables beneficiaries to access information and services seamlessly.

Founder Trustees Dr Rakesh Kalapala and Dr Madhu Vasepalli unveiled DEEP Vision 2030, an ambitious roadmap aimed at transforming 5 million lives through equitable healthcare, quality education, and innovative skill development initiatives.

The event showcased DEEP’s flagship programmes, including DEEP on Wheels (Mobile Health), the Physiotherapy Centre (KGNMT), and education support programmes across schools and Child Care Institutions (CCIs), such as Asritha, Srividhya, VSS, THARA Home, Balyam Home, and Government Special Homes, among others.

It also highlighted skill-building centres for youth and women, scholarships for economically weaker students, and environmental awareness drives. Volunteers and partners were honoured for their invaluable contributions to grassroots development.

Products made by special children from Kasturba Gandhi National Memorial Trust and Sri Vidya Centre for the special children.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk